Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

ConclusionThe combination of ruxolitinib and weekly paclitaxel was well tolerated with evidence of clinical activity. Further analysis of this combination is ongoing (NCT02041429).Trial registrationNCT02041429. Date of registration: January 22, 2014.

Source: Cancer Chemotherapy and Pharmacology - February 14, 2021 Category: Cancer & Oncology Source Type: research